Home Featured Page 133

Featured

Latest

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Psychedelic Funding Update: Q1 2026

Inclius Alvarious’s Place Within Indigenous Society

Reunion Neuroscience Inc. Provides 2023 Corporate Update

FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD...

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for...

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in...

Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”,...

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke...

PT380 – Microdosing, Talking to Physicians About Psychedelics, and Nurses as...

Psychedelics Weekly – Psilocybin and Stress Response, the Minnesota Medical Association...

Clearmind Medicine Announces Shareholders Meeting Results

Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical...

EDITOR PICKS

A Practitioner Statement on the Responsible Development of Ibogaine in the...

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and...

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.